◀ Back to EGFR

EGFR — ERBB4

Pathways - manually collected, often from reviews:

• OpenBEL Selventa BEL large corpus: Complex of EGFR-ERBB4 → BTC (directlyIncreases)
  Evidence: the second group betacellulin (BTC), heparin-binding EGF (HB-EGF), and epiregulin (EPR), which exhibit dual specificity in that they bind ErbB1 and ErbB4.
• OpenBEL Selventa BEL large corpus: EGFR → ERBB4 (increases, EGFR Activity) Cohen et al., J Biol Chem 1996
  Evidence: It was also found that in response to heregulin beta2, endogenous murine HER1 or transfected human HER1 became phosphorylated when HER4 was present. This demonstrates that HER1 and HER4 can exist in a heterodimer complex and likely activate each other by transphosphorylation.
• OpenBEL Selventa BEL large corpus: Complex of EGFR-ERBB4 → EREG (directlyIncreases)
  Evidence: the second group betacellulin (BTC), heparin-binding EGF (HB-EGF), and epiregulin (EPR), which exhibit dual specificity in that they bind ErbB1 and ErbB4.
• OpenBEL Selventa BEL large corpus: Complex of EGFR-ERBB4 → HBEGF (directlyIncreases)
  Evidence: the second group betacellulin (BTC), heparin-binding EGF (HB-EGF), and epiregulin (EPR), which exhibit dual specificity in that they bind ErbB1 and ErbB4.
• BioCarta role of erbb2 in signal transduction and oncology: ERBB2/ERBB 1/3/4 complex (ERBB2-ERBB4_ERBB3_EGFR) → ERBB ligand/ERBB2/ERBB 1/3/4 complex (ERBB2-ERBB4_ERBB3_EGFR) (modification, collaborate)
  
• NCI Pathway Database ErbB receptor signaling network: ErbB4/EGFR/neuregulin 1 beta complex (ERBB4-EGFR-NRG1) → ErbB4 (ERBB4) (modification, collaborate) Hobbs et al., Oncogene 2002, Cohen et al., J Biol Chem 1996
  Evidence: physical interaction
• NCI Pathway Database ErbB receptor signaling network: ErbB4/EGFR/neuregulin 1 beta complex (ERBB4-EGFR-NRG1) → neuregulin 1 beta (NRG1) (modification, collaborate) Hobbs et al., Oncogene 2002, Cohen et al., J Biol Chem 1996
  Evidence: physical interaction
• NCI Pathway Database ErbB receptor signaling network: ErbB4/EGFR/neuregulin 1 beta complex (ERBB4-EGFR-NRG1) → EGFR (EGFR) (modification, collaborate) Hobbs et al., Oncogene 2002, Cohen et al., J Biol Chem 1996
  Evidence: physical interaction
• NCI Pathway Database ErbB receptor signaling network: ErbB4 (ERBB4) → EGFR (EGFR) (modification, collaborate) Hobbs et al., Oncogene 2002, Cohen et al., J Biol Chem 1996
  Evidence: physical interaction
• NCI Pathway Database ErbB receptor signaling network: ErbB4 (ERBB4) → ErbB4/EGFR/neuregulin 4 complex (ERBB4-EGFR-NRG4) (modification, collaborate)
  Harari et al., Oncogene 1999*
  Evidence: physical interaction
• NCI Pathway Database ErbB receptor signaling network: ErbB4 (ERBB4) → EGFR (EGFR) (modification, collaborate) Harari et al., Oncogene 1999*
  Evidence: physical interaction
• NCI Pathway Database ErbB receptor signaling network: ErbB4/EGFR/neuregulin 4 complex (ERBB4-EGFR-NRG4) → EGFR (EGFR) (modification, collaborate) Harari et al., Oncogene 1999*
  Evidence: physical interaction
• NCI Pathway Database ErbB receptor signaling network: ErbB4/EGFR/neuregulin 4 complex (ERBB4-EGFR-NRG4) → neuregulin 4 (NRG4) (modification, collaborate) Harari et al., Oncogene 1999*
  Evidence: physical interaction
• Reactome Reaction: EGFR → ERBB4 (indirect_complex) Cohen et al., J Biol Chem 1996
• Reactome Reaction: EGFR → ERBB4 (reaction) Vijapurkar et al., Exp Cell Res 2003, Walton et al., J Biol Chem 1990, Li et al., Cell Signal 2007, Xu et al., Mol Cell Biol 2007, Hazan et al., Cell Growth Differ 1990, Kaushansky et al., Chem Biol 2008, Helin et al., J Biol Chem 1991, Margolis et al., J Biol Chem 1989, Ricci et al., Oncogene 1995, Wallasch et al., EMBO J 1995, Prigent et al., EMBO J 1994, Soler et al., Oncogene 1994, Segatto et al., Oncogene 1993, Cohen et al., J Biol Chem 1996, Pinkas-Kramarski et al., EMBO J 1996

Protein-Protein interactions - manually collected from original source literature:

Studies that report less than 10 interactions are marked with *

• IRef Biogrid Interaction: EGFR — ERBB4 (physical association, affinity chromatography technology) Meijer et al., Cell Signal 2013*
• IRef Hprd Interaction: EGFR — ERBB4 (in vitro) Fernandes et al., Am J Respir Cell Mol Biol 1999*
• IRef Intact Interaction: ERBB4 — EGFR (physical association, anti bait coimmunoprecipitation) Fernandes et al., Am J Respir Cell Mol Biol 1999*

Text-mined interactions from Literome

Bei et al., J Pathol 2001 (Carcinoma, Squamous Cell...) : Among invasive and in situ carcinoma, EGFR expression was the most prevalent ( in 29/32 and 8/11 cases, respectively ) followed by ErbB2 ( 17/32 and 2/11 ) and ErbB4 ( 9/32 and 1/10 ), while ErbB3 was only detected in invasive tumours ( 12/32 )
Shi et al., Dev Biol 2003 (MAP Kinase Signaling System) : At the molecular level, reduced expression of epidermal growth factor receptor , attenuated protein cleavage of ErbB4 , and changes in MAPK activation were also detected in TACE ( DeltaZn/DeltaZn ) knockout heart tissues
Muraoka-Cook et al., Mol Endocrinol 2008 : We found that full prolactin mediated STAT5A activation and binding to the endogenous beta-casein promoter required ErbB4/HER4 but did not require ErbB1/epidermal growth factor receptor
Frey et al., Lab Invest 2010 (Colonic Neoplasms) : Furthermore, ErbB4 expression promoted EGFR phosphorylation in the presence of heregulin, implicating ErbB4-EGFR heterodimerization in these responses